Ascendis files for IPO

Ascendis Pharma A/S (Hellerup, Denmark) filed to raise up to $86.3 million in an IPO on NASDAQ underwritten by BofA Merrill Lynch; Leerink; and Wells Fargo.

On Monday, Ascendis reported interim Phase II data for its TransCon Growth Hormone in 25 children with growth hormone deficiency. The company said the once-weekly product appeared comparable to daily growth hormone therapies in terms of efficacy, safety and tolerability. Top-line data for all patients in the study are expected in mid-2015. ...